Is size the next big thing in epidemiology?

Epidemiology

Volumn 24, Issue 3, 2013, Pages 349-351

  Toh, Sengwee ^a   Platt, Richard ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANGIONEUROTIC EDEMA; COMPUTER PROGRAM; DATA ANALYSIS; DATA BASE; ELECTRONIC MEDICAL RECORD; EPIDEMIOLOGICAL DATA; HUMAN; METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

AMIDES; ANGIOEDEMA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; EPIDEMIOLOGIC RESEARCH DESIGN; FUMARATES; HUMANS; MULTICENTER STUDIES AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 84876213875     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0b013e31828ac65e     Document Type: Review

References (29)

1. Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angio-edema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med. 2012;172:1582-1589.
2. Vleeming W, Van amsterdam JG, Stricker BH, De Wildt DJ. aCe inhibitor-induced angioedema. incidence, prevention and management. Drug Saf. 1998;18:171-188.
3. Brown NJ, Ray WA, Snowden M, Griffn MR. Black americans have an increased rate of angiotensin converting enzyme inhibitor-associated an-gioedema. Clin Pharmacol Ther. 1996;60:8-13.
4. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. angioedema incidence in US veterans initiating angiotensin-convert-ing enzyme inhibitors. Hypertension. 2008;51:1624-1630.
5. Schneeweiss S, Avorn J. a review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323-337.
6. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. developing the Sentinel System-a national resource for evidence development. N Engl J Med. 2011;364:498-499.
7. Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and drug administration's mini-Sentinel program: status and direction. Pharmacoepide-miol Drug Saf. 2012;21(suppl 1):1-8.
8. Andrade SE, Raebel MA, Boudreau D, et al. Chapter 12: health maintenance organizations/health plans. in: Strom BL, Kimmel SE, Hennessy S, Eds. Pharmacoepidemiology. 5th ED. Chichester, UK: Wiley-Blackwell; 2012.
9. Platt R, Davis R, Finkelstein J, et al. multicenter epidemiologic and health services research on therapeutics in the hmo Research network Center for education and Research on Therapeutics. Pharmacoepidemiol Drug Saf. 2001;10:373-377.
10. Wagner EH, Greene SM, Hart G, et al. Building a research consortium of large health systems: the Cancer Research network. J Natl Cancer Inst Monogr. 2005; 3-11.
11. Go AS, Magid DJ, Wells B, et al. The Cardiovascular Research network: a new paradigm for cardiovascular quality and outcomes research. Circ Cardiovasc Qual Outcomes. 2008;1:138-147.
12. Chen RT, Glasser J W, Rhodes PH, et al. Vaccine Safety datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety datalink Team. Pediatrics. 1997;99:765-773.
13. Stang PE, Ryan PB, Racoosin JA, et al. advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010;153:600-606.
14. Coloma PM, Schuemie MJ, Trifrò G, et al; eU-adR Consortium. Combining electronic healthcare databases in europe to allow for large-scale drug safety monitoring: the eU-adR project. Pharmacoepidemiol Drug Saf. 2011;20:1-11.
15. Offce of the national Coordinator for health information Technology. Query health project Charter. available at: http://Queryhealth.org. accessed 19 September 2011.
16. Maro JC, Platt R, Holmes JH, et al. design of a national distributed health data network. Ann Intern Med. 2009;151:341-344.
17. Brown JS, Holmes JH, Shah K, Hall K, Lazarus R, Platt R. distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of care. Med Care. 2010;48(6 suppl):S45-S51.
18. Toh S, Platt R, Steiner J F, Brown JS. Comparative-effectiveness research in distributed health data networks. Clin Pharmacol Ther. 2011;90:883-887.
19. Rassen JA, Moran J, Toh D, et al. evaluating strategies for data sharing and analyses in distributed data setting. http://www.mini-sentinel. org/work-products/Statistical-methods/mini-Sentinel-methods-evalu-ating- Strategies-for-data-Sharing-and-analyses.pdf. accessed 28 February 2013.
20. Rassen JA, Solomon DH, Curtis JR, Herrinton L, Schneeweiss S. privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. Med Care. 2010;48(6 suppl):S83-S89.
21. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70:41-55.
22. Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemio-logic studies. Stat Methods Med Res. 2009;18:67-80.
23. Fireman B, Lee J, Lewis N, Bembom O, Van der laan M, Baxter R. infu-enza vaccination and mortality: differentiating vaccine effects from bias. Am J Epidemiol. 2009;170:650-656.
24. Karr AF, Lin X, Sanil a P, Reiter J p. Secure regression on distributed databases. J Comput Graph Stat. 2005; 14:263-279.
25. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. high-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512-522.
26. Toh S, García Rodríguez LA, Hernán MA. Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. Pharmacoepidemiol Drug Saf. 2011;20:849-857.
27. Rassen JA, Schneeweiss S. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf. 2012;21(suppl 1):41-49.
28. Curtis LH, Weiner MG, Boudreau DM, et al. design considerations, architecture, and use of the mini-Sentinel distributed data system. Pharma-coepidemiol Drug Saf. 2012;21(suppl 1):23-31.
29. Cutrona SL, Toh S, Iyer A, et al. Validation of acute myocardial infarction in the Food and drug administration's mini-Sentinel program. Pharma-coepidemiol Drug Saf. 2013;22:40-54.